SCHEMBL6077321

SCHEMBL6077321

CON(Cc1ccccc1C)C(=O)C=C1OC(C)(C)OC1=O

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC1A5 Q15758 1/20 0.32
BCHE P06276 1/20 0.32
ACHE P22303 1/20 0.32
LMNA P02545 1/20 0.32
MAOB P27338 1/20 0.32
ALDH1A1 P00352 2/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
GPR84 Q9NQS5 1/20 0.31
CDK4 P11802 1/20 0.31
CCND1 P24385 1/20 0.31
TAS2R14 Q9NYV8 2/20 0.31
MAPT P10636 1/20 0.31
HSP90AA1 P07900 1/20 0.31
KDM4E B2RXH2 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
THRA P10827 1/20 0.30
THRB P10828 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6077318 1.00 SLC1A5 (0.32) SLC1A5BCHEACHELMNAMAOB
SCHEMBL6077300 0.87 KMT2A (0.37) LMNAMAOBALDH1A1MEN1KMT2A
SCHEMBL6077281 0.87 KMT2A (0.37) LMNAMAOBALDH1A1MEN1KMT2A
SCHEMBL6077728 0.85 CYP1A2 (0.38) LMNAALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL6077726 0.85 CYP1A2 (0.38) LMNAALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL6879189 0.84 NPSR1 (0.36) ACHEALDH1A1L3MBTL1MAPT
SCHEMBL6078334 0.84 TSPO (0.35) SLC1A5BCHEACHELMNAALDH1A1
SCHEMBL6449486 0.84 TSPO (0.35) SLC1A5BCHEACHELMNAALDH1A1
SCHEMBL6879078 0.82 POLB (0.34) LMNAALDH1A1L3MBTL1MAPTTHRB
SCHEMBL6077334 0.82 POLB (0.34) LMNAALDH1A1L3MBTL1MAPTTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7109186-B2 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment BRISTOL-MYERS SQUIBB COMPANY (US) 2006-09-19 US disclosed
EP-1467695-A2 HIV INTEGRASE INHIBITORS Bristol-Myers Squibb Company (US) 2004-10-20 EP disclosed
US-6777440-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-08-17 US disclosed
US-20040110804-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-06-10 US disclosed
WO-2004004657-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-01-15 WO disclosed
US-20030176495-A1 HIV Integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2003-09-18 US disclosed
WO-2003049690-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110804-A1 HIV integrase inhibitors CDKN1A, SAMHD1, CTCF SLC1A5 2626/4885BCHE 2523/4885ACHE 2868/4885
US-20030176495-A1 HIV Integrase inhibitors MAPT, RIF1, HPRT1 SLC1A5 824/4885BCHE 2190/4885ACHE 3434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.